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Abstract
Background: Minocycline is an oral tetracycline derivative with good bioavailability in the central nervous system (CNS).
Minocycline, a potent inhibitor of matrix metalloproteinase (MMP)-9, attenuates disease activity in experimental
autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Potential adverse effects associated
with long-term daily minocycline therapy in human patients are concerning. Here, we investigated whether less frequent
treatment with long-circulating polyethylene glycol (PEG) minocycline liposomes are effective in treating EAE.
Findings: Performing in vitro time kinetic studies of PEG minocycline-liposomes in human peripheral blood mononuclear
cells (PBMCs), we determined that PEG minocycline-liposome preparations stabilized with CaCl2 are effective in diminishing
MMP-9 activity. Intravenous injections of PEG minocycline-liposomes every five days were as effective in ameliorating
clinical EAE as daily intraperitoneal injections of minocycline. Treatment of animals with PEG minocycline-liposomes
significantly reduced the number of CNS-infiltrating leukocytes, and the overall expression of MMP-9 in the CNS. There was
also a significant suppression of MMP-9 expression and proteolytic activity in splenocytes of treated animals, but not in CNS-
infiltrating leukocytes. Thus, leukocytes gaining access to the brain and spinal cord require the same absolute amount of
MMP-9 in all treatment groups, but minocycline decreases the absolute cell number.
Conclusions: Our data indicate that less frequent injections of PEG minocycline-liposomes are an effective alternative
pharmacotherapy to daily minocycline injections for the treatment of CNS autoimmune diseases. Also, inhibition of MMP-9
remains a promising treatment target in EAE and patients with MS.
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Introduction
Experimental autoimmune encephalomyelitis (EAE) is an
antigen-specific T cell-mediated autoimmune diseases of the
central nervous system (CNS), which has long served as an
animal model for the human demyelinating disorder multiple
sclerosis (MS) [1]. A pathological hallmark of EAE is the
presence of perivascular mononuclear cell infiltrates in the brain
and spinal cord [1]. In order to egress from the peripheral blood
into peripheral tissues, leukocytes have to transverse endothelial
barriers, the basement membrane (basal lamina), and parenchy-
mal extracellular matrix (ECM). Matrix metalloproteinases
(MMPs) are proteolytic enzymes that mediate leukocyte
migration across the blood-brain barrier (BBB), and through
ECM [2–6].
Minocycline is an oral tetracycline derivative with good
bioavailability within the CNS. It was shown previously that
minocycline attenuates neuroinflammation, neuropathological
changes, and clinical disease severity in EAE [7–9]. The biological
effects of minocycline in EAE appear to be at least partially
mediated through its effect on the expression and biological
activity of MMP-9 [8]. Clinical trials of minocycline in patients
with MS are ongoing. Systemic administration of minocycline has
been associated with numerous, sometimes serious adverse effects.
Liposomes are spherical vesicles that consist of one or more lipid
bilayers that surround an aqueous space. Liposomes were
developed as drug carriers because of their capability to enclose
biological materials, and to deliver them to specific tissues. Long-
circulating polyethylene glycol (PEG) liposomes have two
interesting pharmacological properties: (1) Following administra-
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4151tion, PEG liposomes remain intact in the blood compartment for
extended periods of time; (2) PEG liposomes have a high affinity
to, and accumulate predominantly within sites of inflammation
[10].
The principal goal of this study was to test the treatment efficacy
of PEG minocycline-liposomes in EAE, and to study their effect on
MMP-9 expression by leukocytes in peripheral lymphoid organs
and the CNS.
Figure 1. Effects of long-circulating polyethylene glycol (PEG) minocycline-liposomes on the human peripheral blood mononuclear
cells (PBMC) in vitro. Quantitative analysis of the zones of gelatinolysis detected the reduced the proteolytic activity of matrix metalloproteinase
(MMP)-9 in the human PBMC sample treated with minocycline (3.0 mg/ml) compared with findings in controls (PBS). A more significant decrease of
MMP-9 activity was detected in cells treated with minocycline for 6 hours compared to cells that were treated for 1 hour (A). At 1 hour, there was no
significant MMP-9 activity difference among samples treated by the different PEG liposome preparation either with glucose, CaCl2 or MgCl2 (A). Time
kinetic studies of PEG minocycline-liposomes in vitro revealed that the MMP-9 gelatinolytic activity is significantly reduced at 6 hours after incubation
samples with PEG liposome+minocycline (B). Moreover, PEG minocycline-liposome+CaCl2 treatment inhibited the MMP-9 activity more strikingly than
the PEG minocycline-liposome+MgCl2 preparation (B). Gelatinolytic activity was detectable by gelatin-zymography at molecular weights of 92 kDa,
indicative of MMP-9, in the supernatants from all human PBMC samples studied. Incubation with PEG minocycline-liposomes with CaCl2 resulted in
remarkably decreased sizes of the bands at 92 kDa, pointing to decreased activation of MMP-9 in comparison with PEG minocycline-liposomes with
MgCl2 or glucose, respectively (C).
doi:10.1371/journal.pone.0004151.g001
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In vitro effects of PEG minocycline-liposomes on MMP-9
expression by human PBMCs
Proteolytic activity of MMP-9 was assessed in supernatants of
human PBMCs after 24 hrs of stimulation with IL-2 and assessed
by gelatin-zymography, as previously described [5,11]. Densito-
metric analysis of the zones of gelatinolysis revealed a reduced
proteolytic activity of MMP-9 in those supernatants derived from
PBMCs treated with minocycline (3.0 mg/ml) compared to
control (PBS). Specifically, the reduction of MMP-9 proteolytic
activity following PEG minocycline-liposomes treatment was
Figure 2. Effects of long-circulating polyethylene glycol (PEG) minocycline-liposomes on the clinical course of experimental
autoimmune encephalomyelitis (EAE). A single intravenous (i.v.) injection of PEG minocycline-liposomes given after disease onset at day 15
post-immunization resulted in significant amelioration of clinical disease for eight days compared to a single injection of PBS when given shortly after
onset of clinical disease (A). This effect was not sustained (A). In subsequent experiments, PEG-liposomes were administered every five days.
Treatment with i.v. PEG minocycline-liposomes initiated after disease onset at day 15 post-immunization and administered every five days was as
effective in ameliorating clinical EAE as treatment with daily intraperitoneal (i.p.) injections of minocycline (B). In contrast, i.v. injections of empty PEG-
liposome every five days, or minocycline i.p. injections every five days had no detectable effect on the clinical course of EAE (B). The time of treatment
initiation is indicated by a red arrow.
doi:10.1371/journal.pone.0004151.g002
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after 1 hour, both with PEG minocycline-liposome preparations
containing CaCl2 or MgCl2 (Fig. 1A). When time kinetic studies
of PEG minocycline-liposomes were performed in vitro,w e
detected that PEG minocycline-liposomes with CaCl2 inhibited
the proteolytic activity of MMP-9 more strikingly than PEG
minocycline-liposomes with MgCl2 or glucose (Fig. 1B&C).
Incubation with PEG minocycline-liposomes with CaCl2 resulted
in a substantial decrease of MMP-9 proteolytic activity
compared with PEG minocycline-liposomes with MgCl2 or
glucose, respectively (Fig. 1C). Consequently, PEG minocycline-
liposome preparations containing CaCl2 were used in all EAE
experiments.
Effects of PEG minocycline-liposomes on the clinical
course of EAE
To test our hypothesis that less frequent intravenous (i.v.)
injections of a liposome formulation have similar therapeutic
efficacy as daily injections of regular formulation minocycline, we
employed treatment paradigms that did not favor our hypothesis.
Other investigators had previously shown that a daily intraperi-
toneal (i.p.) treatment paradigm in itself may significantly lower
clinical disease in mice with EAE, possibly through the release of
anti-inflammatory mediators [9]. In initial experiments, a single
dose of PEG minocycline-liposomes was administered after EAE
disease onset at day 15 post-immunization to determine the
duration of efficacy of this preparation. A single i.v. injection of
PEG minocycline-liposomes resulted in significant amelioration of
clinical disease for eight days compared to a single injection of PBS
(Fig. 2A). This beneficial effect was not sustained (Fig. 2A).
Consequently, it was decided to administer PEG-liposomes every
five days. In clinical practice, the earliest possible time of treatment
initiation in patients with MS is after the first clinical attack [12].
Thus, therapy was started at day 15 post immunization, after
experimental animals had developed clinical disease. Treatment
with i.v. PEG minocycline-liposomes every five days was as
effective in ameliorating clinical EAE as treatment with daily i.p.
injections of minocycline (Fig. 2B, Table 1). Both treatment
paradigms resulted in sustained clinical benefit. In contrast, i.v.
injections of empty PEG-liposomes every five days, or minocycline
i.p. injections every five days had no detectable effect on the
clinical course of EAE (Fig. 2B, Table 1).
Effects of PEG minocycline-liposomes on CNS
inflammation
A decreased number of inflammatory foci in the brain of EAE
mice treated with PEG minocycline-liposomes was observed five
days after treatment initiation (Fig. 3A). Specifically, the number of
CD11b
+ macrophages, CD3
+ T lymphocytes, and the overall
expression of MMP-9 within CNS tissue was decreased by PEG
minocycline-liposomes treatment (Fig. 3A–B). There was no
difference with regard to the numbers of immunoreactive cells
between mice that were treated daily with i.p. minocycline, and
animals treated with i.v. PEG minocycline-liposomes (Fig. 3B).
Effects of PEG minocycline-liposomes on the expression
of MMP-9 in splenocytes and CNS-infiltrating leukocytes
The expression of MMP-9 by splenocytes was significantly
reduced in mice treated daily with i.p. injections of minocycline
and i.v. injections of PEG minocycline-liposomes every five days
compare to splenocytes from animals that received no treatment, i.p.
injections of minocycline every five days, and i.v. injections of empty
PEG-liposomes every five days, as shown by ELISA (Fig. 4A). As
expected, MMP-9 proteolytic activity measured by zymography was
also significantly diminished in mice treated daily with i.p. injections
of minocycline and i.v. injections of PEG minocycline-liposomes
every five days (Fig. 4B). The protein expression of MMP-9 by CNS-
infiltrating leukocytes was similar in all treatment groups (Fig. 4C).
There was no significant difference with regard to the number of
CD11b
+ macrophages, CD3
+ T lymphocytes, and the expression of
MMP-9 in the CNS between animals that had received no
treatment, daily i.p. PBS injection, and empty PEG-liposomes
administered i.v. every five days (data not shown).
Discussion
Minocycline, a semisynthetic tetracycline, is used for the
treatment of pneumonia, rheumatoid arthritis (RA), acne, and
other infectious diseases. Furthermore, it has been successfully
tested in animal models of neurodegeneration, CNS inflammation,
and traumatic brain injury [13]. It is currently thought that the
clinical benefits achieved by minocycline are the result of caspase-
activated apoptosis, and its modulation of peripheral immuno-
competent cells and microglia with regard to their release of
cytokines, suppression of free radical production, and inhibition of
Table 1. Summary of the EAE disease course
a.
Treatment No. of Mice Incidence
b (%) Mortality
c (%) Average Day of Onset Average Cumulative Disease Score
d
No Tx
e 5 5/5 (100) 0 17 3266
Mino
f (q5d) 5 5/5 (100) 0 17 3364
Lipo
g (q5d) 5 5/5 (100) 1 (20) 17 3269
Mino
h (daily) 5 5/5 (100) 0 15 2161
Mino-Lipo
i (q5d) 5 5/5 (100) 0 15 1862
aGraded disease score as described in Materials and Methods.
bRepresents the percentage of mice that developed a clinical score of at least one.
cRepresents the percentage of mice that died or were sacrificed for humane purposes.
dThe cumulative disease score was calculated by adding the disease score from the day of onset to day 30. The values shown are the mean6SE of all the mice with
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treatment may worsen some diseases of the CNS [13] and the
peripheral nerve [14]. Thus, minocycline might have therapeutic
potential in neuroinflammatory disorders. However, long-term
safety and efficacy need to be determined critically when
considering its application in clinical neurology.
Minocycline has an acceptable side-effect profile and tolerability
when utilized for short-term antibiosis. Potential adverse effects
associated with long-term daily minocycline therapy for patients
with MS are concerning. These potential side effects have perhaps
most frequently been observed in patients with RA. In a
randomized, double-blind study of minocycline in patients with
active RA, patients received a maximal oral daily dose of 200 mg
for 26 weeks [15]. Six out of 40 patients stopped medication
because of adverse events in the minocycline treatment group.
Specifically, gastrointestinal adverse effects and dizziness were
among the adverse events significantly increased in the minocy-
cline group compared to those patients receiving placebo. Other
adverse events that were more frequent in the minocycline
treatment group included rash and headaches. Long-term
exposure to minocycline has also been associated with a variety
of clinical and serological autoimmune aberrations, including
serum sickness [16], drug-induced lupus [17], autoimmune
hepatitis [18], and vasculitis [19].
Some of the observed adverse events are not entirely surprising.
Minocycline is a small (495 kDa), highly lipophilic molecule capable
of crossing the blood–brain barrier (BBB). Because of the large
volume of distribution of minocycline, the drug accumulates in
tissues other than the CNS, including the eye and prostate, and it is
detectable in high concentration in tears, saliva and breast milk [20].
The pharmacological half-life of minocycline is approximately
18 hours. Thus, high and frequent dosing is required.
Preliminary data on the efficacy of minocycline in patients with
MS are promising. In an ongoing clinical trial of minocycline in a
relatively small number of patients with relapsing-remitting MS,
study participants received oral minocycline 100 mg twice daily
for 6 months after a 3-month run-in period [21]. A 30-month
treatment extension is ongoing. The preliminary results of this trial
demonstrated that minocycline therapy reduces gadolinium-
enhancing lesions on magnetic resonance imaging (MRI) [21].
Fortunately, no serious adverse effects of minocycline in MS have
been reported thus far.
As our study in EAE animals shows, pharmacotherapy with
long-circulating PEG minocycline-liposomes would substantially
lower the total amount of minocycline administered to patients,
yet provide similar clinical effectiveness. Thus, the risk of potential
side effects of minocycline could be minimized. In our experi-
ments, PEG minocycline-liposomes provided a sustained clinical
benefit when given every five days, but not when given less
frequently. The total expression of MMP-9 within the CNS and by
splenocytes, a robust biomarker of minocycline activity, was also
equally effected by daily minocycline treatment and injections with
PEG minocycline-liposomes every five days. Interestingly, the
expression of MMP-9 by CNS-infiltrating leukocytes was similar in
all treatment groups, indicating that there is an absolute
requirement for a certain level of MMP-9 expression by leukocytes
to migrate across the blood-brain barrier, and to gain access to
areas of inflammation. The absolute number of infiltrating cells
was decreased.
Our present data emphasize the potential role of PEG liposomes
as a drug delivery system for pharmaceuticals for CNS
autoimmune diseases. Our data also indicate that inhibition of
MMP-9 remains a promising treatment target in patients with MS.
Materials and Methods
Preparation of long-circulating PEG–liposomes
A lipid solution was prepared in ethanol, containing 100 mM
dipalmitoyl phosphatidylcholine (DPPC), 8.1 mM PEG 2000
distearyl phosphatidylethanolamine (DSPE) (Lipoid GmbH,
Ludwigshafen, Germany) and 54 mM cholesterol (Sigma, Poole,
UK) in a molar ratio of 1.85:0.15:1.0. The lipid solution was
transferred to a round-bottom flask, and a lipid film was created
by rotary evaporation. The film was hydrated with a solution of
120 mM calcium chloride and 120 mM sodium acetate (MP
Biomedicals, Inc., Eschwege, Germany). The resulting lipid
dispersion was sized by multiple extrusions through polycar-
bonate filter membranes. Unencapsulated calcium chloride and
sodium acetate was removed by dialysis. Mean particle size was
determined by dynamic light scattering with a Malvern 4700
system (Malvern, Worcestershire, UK). The diameter of the
liposomes was determined to be 100–110 nm with a polydis-
persity index below 0.2. To 8 ml liposomal formulation, 80 mg
minocycline hydrochloride (MP Biomedicals Inc.) was added.
This mixture was incubated at 50uC for 15 minutes. Phospho-
l i p i dc o n t e n tw a sd e t e r m i n e db yp h o s p h a t ea s s a y[ 2 2 ]i nt h e
organic phase after extraction of liposomal preparations with
chloroform. The aqueous phase after extraction was used for
reversed-phase HPLC-determination of the minocycline con-
tent.
In vitro assessment of mononuclear cells
Peripheral blood was aseptically collected from healthy
volunteers by standard venipuncture into vacuum tubes containing
sodium heparin as anticoagulant. PBMCs were isolated by Ficoll-
Hypaque (Pharmacia, Karlsruhe, Germany) density gradient
centrifugation and resuspended (2610
6/ml) in complete culture
media consisting of RPMI 1640 medium supplemented with 10%
human serum, 2 mM glutamine (Sigma-Aldrich, Munich, Ger-
many), 100 U/ml penicillin, and 100 IE/ml streptomycin (Invi-
trogen, Karlsruhe, Germany). PBMCs were cultured for 24 h at
37uC and 5% CO2 in the presence of IL-2 (10 ng/ml; Sigma-
Aldrich). Afterwards, PEG-liposomes were added and superna-
tants were obtained 1 and 6 h later. Informed written consent was
obtained from all healthy volunteers, and all study procedures
were approved by the Institutional Review Board at the Heinrich
Heine University.
Figure 3. Effects of long-circulating polyethylene glycol (PEG) minocycline-liposomes on inflammation within the central nervous
system (CNS). A decreased number of inflammatory foci in the brain of mice with experimental autoimmune encephalomyelitis (EAE) treated with
PEG minocycline-liposomes at disease onset was detected (A). Specifically, the number of CD11b
+ macrophages, CD3
+ T lymphocytes, and the overall
expression of matrix metalloproteinase (MMP)-9 were decreased by PEG minocycline-liposomes treatment (A,B). There was no difference with regard
to the numbers of immunoreactive cells between mice that were treated daily with intraperitoneal (i.p.) minocycline, and animals that had received
intravenous (i.v.) PEG minocycline-liposomes (B). There was no difference with regard to the number of CD11b
+ macrophages, CD3
+ T lymphocytes,
and the expression of MMP-9 in the CNS between animals that had received no treatment, daily i.v. PBS injection, and empty PEG-liposomes
administered i.p every five days (data not shown).
doi:10.1371/journal.pone.0004151.g003
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infiltrating leukocytes. The expression levels of MMP-9 were significantly down-regulated on day 20 after active induction of experimental
autoimmune encephalomyelitis (EAE) in splenocytes of mice following treatment with daily intraperitoneal (i.p.) injections of minocycline, and after
intravenous (i.v.) injections of PEG minocycline-liposomes every 5 days compared to experimental animals that received no treatment, that were
treated with i.v. injections of empty PEG-liposome every five days, or with minocycline i.p. injections every five days, as shown by ELISA (A). The
proteolytic activity of MMP-9 measured by zymography was also significantly diminished in mice treated daily with i.p. injections of minocycline and
i.v. injections of PEG minocycline-liposomes every five days (B). MMP-9 protein expression in CNS mononuclear cells was not found to be significantly
different between experimental groups (C).
doi:10.1371/journal.pone.0004151.g004
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Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS/PAGE) zymography was performed for determination of
gelatinase activity as described before [5,11]. Supernatants were
mixed 1:1 with Tris/glycine SDS sample buffer (Novex, CA),
and samples were applied to a 10% (w/v) polyacrylamide
resolving gel containing 0.1% SDS and 0.1% gelatin type A from
porcine skin (Sigma-Aldrich). Stacking gels were 5% (w/v)
polyacrylamide. After electrophoresis gels were washed in
renaturing buffer (Novex) containing Triton X-100 to remove
any SDS and incubated in developing buffer (Novex) for
18 hours at 37uC. Gels were stained for 6 hours in 30%
methanol / 10% acetic acid containing 0.5% (w/v) Coomassie
Brilliant Blue G-250 and destained in the same buffer without
dye. Gelatinase activity was detected as unstained bands on a
blue background representing areas of gelatin digestion. As a
negative control, gels were incubated with 10 mol/L N-
ethylenediaminetetraacetic acid (EDTA) prior to the activation
of gelatinases in parallel. Images of gels were captured by
scanning on a flatbed scanner. A standard curve was obtained
for densitometric quantitation of MMP activity using purified
MMP-2 and -9 (Chemicon, CA). In each sample, MMP-9
proteolytic activity was calculated using an electrophoretic gel
lane calculation software after image inversion.
Mice
Female C57BL/6 (B6) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). The use of mice in these
experiments was approved by the Institutional Animal Care and
Research Advisory Committee at the University of Texas
Southwestern Medical Center at Dallas.
Experimental autoimmune encephalomyelitis
EAE was induced in groups of five 6–10 week old female
C57BL/6 mice by immunization with 200 mg of myelin
oligodencrocyte glycoprotein (MOG) petide (p) 35–55 (BioSource
International, CA) in an emulsion with Complete Freund adjuvant
(CFA) containing 4 mg ml
21 of heat-inactivated Mycobacterium
tuberculosis H37Ra (Difco Laboratories, MI). On the day of
immunization and 48 hours later, C57BL/6 mice were injected
with 200 ng pertussis toxin (PTx, List Biological Laboratories, Inc.,
CA) in phosphate buffered saline (PBS) i.p. Mice were examined
daily for clinical signs of EAE and scored as follows: 0: No
paralysis; 1: Loss of tail tone; 2: Hindlimb weakness; 3: Hindlimb
paralysis; 4: Hindlimb and forelimb paralysis; 5: Moribund or
death [23]. All experiments were repeated twice.
Pharmacotherapy
For EAE treatment, the mice were treated with i.v. injections of
PEG minocycline-liposomes (50 mg/g body weight [BW] in 100 ml
of PBS) every five days. Empty PEG-liposomes (50 mg/g BW in
100 ml of PBS), i.p injections of minocycline (50 mg/g BW in
100 ml of PBS) every five days, and not pharmacological treatment
constituted negative controls. Daily i.p. injections of minocycline
(50 mg/g BW in 100 ml of PBS) was the positive control. In one
dosing experiment, a single dose of i.v. injection of PEG
minocycline-liposomes or PBS (control) was given at disease onset.
Histopathological evaluation
Inflammatory infiltrates in the brain were quantified by
haematoxylin and eosin (H&E) staining, as well as immunohisto-
chemistry using antibodies against CD3, CD11b, and MMP-9 on
days 20 after active immunization according to published methods
[11,24]. Selected brain, thoracic and lumbar spinal cord sections
were evaluated by an examiner blinded to the treatment status of
the experimental animals. Three mice per treatment group were
examined. The mice selected for histopathological evaluation had
the mean disease score of their respective treatment group.
Preparation of CNS mononuclear cells
Mononuclear cells were isolated from brains and spinal cords as
described [25]. CNS tissue was passed through a cell strainer
(70 mm). After centrifugation, cells were resuspended in 37%
Percoll (GE Healthcare, WI), centrifuged at 2,118 g for 15 min,
and washed. To prepare cells for experiments, pooled CNS
samples were washed twice with 37% Percoll, resuspended in 30%
Percoll, and layered over 70% Percoll. Cells harvested from the
gradient interface were washed and resuspended in culture
medium consisted of RPMI 1640 (Invitrogen, CA) supplemented
with L-glutamine (2 mM) (Mediatech Inc. VA), sodium pyruvate
(1 mM) (Mediatech), non-essential amino acids (0.1 mM) (Media-
tech), penicillin (100 U ml
21) (Mediatech), streptomycin
(0.1 mg ml
21) (Mediatech), 2-mercaptoethanol (5610
25 M)
(Mediatech) and 10% (v/v) fetal bovine serum (Mediatech) for
further analysis.
Enzyme immunoassay
Supernatants from splenocytes and CNS mononuclear cells
cultured with MOGp35–55 (2 ug/ml) were used for analysis. The
concentration of total MMP-9 (pro-MMP-9, active MMP-9, and
tissue inhibitor of matrix metalloproteases [TIMP]-1-complexed
MMP-9) in cell culture supernatants was determined by
Quantikine Mouse MMP-9 (total) Immunoassay according to
the manufacturer’s instructions (R&D Systems, MN). The results
of ELISA experiments are expressed as an average of triplicate
wells 6standard deviation (SD). A SOFTmax ELISA plate reader
and software was used for data analysis (Molecular Devices, CA).
Statistical analysis
The means of two normally distributed samples were compared
by Student t-test. All other statistical comparisons between groups
were examined using one-way multiple range ANOVA test for
multiple comparison. P-values,0.05 were considered significant.
Data are shown with SD of the mean.
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